Pervin Topçuoğlu

Pervin Topçuoğlu

Auto-generated profile, based on publicly available information

Pervin Topçuoğlu

Ankara University Faculty of Medicine, Department of Hematology, Ankara, Türkiye

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2018 in Balkan Medical Journal
Verified
Journal Article
Open access
GSGuldane Cengiz Seval
Guldane Cengiz Seval
PTPervin Topçuoğlu
Pervin Topçuoğlu
TDTaner Demirer
Taner Demirer
Hematopoietic stem cell transplantation is an established treatment for wide range of malignant and non-malignant conditions. Non-infectious pulmonary complications still remain a leading cause of morbidity and mortality in these patients. Treatment of hematopoietic stem cell transplantation recipients with non-infectious pulmonary complications is still challenging, treatment armamentarium and strategies, currently, are not adequate for patients receiving hematopoietic stem cell transplantation. Future trials are needed for better description of the pathogenesis and complete diagnostic criteria as well as effective therapeutic approaches to non-infectious pulmonary complications in the hematopoietic stem cell transplantation recipients. This report will outline the incidence, risk factors, pathogenesis, clinical spectrum, and discuss the current approaches to management of non-infectious pulmonary complications of hematopoietic stem cell transplantation.

5 October 2011 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
PTPervin Topcuoglu
Pervin Topcuoglu
MAMutlu Arat
Mutlu Arat
MOMuhit Ozcan
Muhit Ozcan
OAOnder Arslan
Onder Arslan
OIOsman Ilhan
Osman Ilhan
GGGunhan Gurman
Gunhan Gurman

24 February 2022 in Turkish Journal of Hematology
Verified
Journal Article
Open access
SBSinem Civriz Civriz Bozdag
Sinem Civriz Civriz Bozdag
GSGuldane Cengiz Seval
Guldane Cengiz Seval
IYIpek Yonal-Hindilerden
Ipek Yonal-Hindilerden
FHFehmi Hindilerden
Fehmi Hindilerden
NANeslihan Andıç
Neslihan Andıç
GÖGüner Hayri Özsan
Güner Hayri Özsan
Objective: Patients with solid malignancies are more vulnerable to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection than the healthy population. The outcome of SARS-CoV-2 infection in highly immunosuppressed populations, such as in patients with hematological malignancies, is a point of interest. We aimed to analyze the symptoms, complications, intensive care unit admissions, and mortality rates of patients with hematological malignancies infected with SARS-CoV-2 in Turkey. Materials and Methods: In this multicenter study, we included 340 adult and pediatric patients diagnosed with SARS-CoV-2 from March to November 2020. Diagnosis and status of primary disease, treatment schedules for hematological malignancies, time from last treatment, life expectancy related to the hematological disease, and comorbidities were recorded, together with data regarding symptoms, treatment, and outcome of SARS-CoV-2 infection. Results: Forty four patients were asymptomatic at diagnosis of SARSCoV-2 infection. Among symptomatic patients, fever, cough, and dyspnea were observed in 62.6%, 48.8%, and 41.8%, respectively. Sixtynine (20%) patients had mild SARS-CoV-2 disease, whereas moderate, severe, and critical disease was reported in 101 (29%), 71 (20%), and 55 (16%) patients, respectively. Of the entire cohort, 251 (73.8%) patients were hospitalized for SARS-CoV-2. Mortality related to SARS-CoV-2 infection was 26.5% in the entire cohort; this comprised 4.4% of those patients with mild disease, 12.4% of those with moderate disease, and 83% of those with severe or critical disease. Active hematological disease, lower life expectancy related to primary hematological disease, neutropenia at diagnosis of SARS-CoV-2, ICU admission, and first-line therapy used for coronavirus disease-2019 treatment were found to be related to higher mortality rates. Treatments with hydroxychloroquine alone or in combination with azithromycin were associated with a higher rate of mortality in comparison to favipiravir use. Conclusion: Patients with hematological malignancy infected with SARS-CoV-2 have an increased risk of severe disease and mortality.

13 July 2009 in Bone Marrow Transplantation
Verified
Journal Article
Open access
TOT Ozcelik
T Ozcelik
PTP Topcuoglu
P Topcuoglu
MBM Beksac
M Beksac
MOM Ozcan
M Ozcan
MAMutlu Arat
Mutlu Arat
TDT Demirer
T Demirer
The optimal timing for recombinant human (rh)G-CSF administration after chemotherapy for PBSC mobilization has not yet been determined. In this study, we compared two different time schedules of rhG-CSF; 4th (early) vs 7th day (late), in 48 consecutive patients with multiple myeloma and lymphoma undergoing PBSC mobilization with CE (CY 4 g/m2 on day 1 and etoposide 200 mg/m2 on days 1–3). The rhG-CSF dose was 10 μg/kg/day for all patients. Both groups were comparable in terms of sex, age and number of previously given different chemotherapy regimens. Duration of neutropenia, CD34+ cell count on the first day of apheresis and numbers of aphereses were not statistically different between the two arms. However, the number of doses of rhG-CSF up to the first cycle of apheresis procedures was significantly lower in the late group than in the early group (P=0.005). The median number of total CD34+ cells collected was 10.54 × 106/kg (range 0.11–37.27) in the early group and 10.81 × 106/kg (range 0.17–49.83) in the late group of rhG-CSF (P=0.781). We conclude that PBSC mobilization after late use of rhG-CSF is an effective approach and therefore, in routine clinical practice, late rhG-CSF may be used for PBSC collections after chemotherapy-based mobilization regimens in this cost-conscious era.

19 December 2019 in Turkish Journal of Hematology
Verified
Journal Article
Open access
EAErden Atilla
Erden Atilla
CAcan ateş
can ateş
AUAtilla Uslu
Atilla Uslu
PAPınar Ataca Atilla
Pınar Ataca Atilla
IDIstar Dolapcı
Istar Dolapcı
PTPervin Topcuoğlu
Pervin Topcuoğlu
Objective: BK virus (BKV) infection has been shown to be related to hemorrhagic cystitis (HC) in allogeneic hematopoietic stem cell transplantation (allo-HSCT). There are conflicting data regarding the association between BKV titers in plasma and clinical disease as well as the risk factors for BKV-related HC. Our aim is to study the risk factors and relationship with plasma BK viral load for development of HC in a prospective analysis. Materials and Methods: We prospectively evaluated 59 patients who received allo-HSCT between 2014 and 2016 by quantitative BK virus polymerase chain reaction (PCR) (Altona Diagnostics, Germany) from blood samples at days 0, 30, 60, and 90 after allo-HSCT. The patients were monitored for signs and symptoms of HC. Results: HC was diagnosed in 22 patients (37 %) at a mean of 100 days (range: 0-367 days). In multivariate analysis, the usage of cyclophosphamide (sub-distribution hazard ratio [sdHR]: 7.82, confidence interval [CI]: 1.375-39.645, p=0.02), reactivated CMV (sdHR: 6.105, CI: 1.614-23.094, p=0.008), and positive BKV viremia (sdHR: 2.15, CI: 1.456-22.065, p=0.01) significantly increased the risk of developing HC. Patients with higher viral loads at day 30 and day 60 were diagnosed with more severe HC (p101.5 copies/mL at day 0 (sensitivity 0.727, specificity 0.875), >98.5 copies/mL at day 30 (sensitivity 0.909, specificity 0.875), and >90.0 copies/mL at day 60 (sensitivity 0.909, specificity 0.875) were indicative of HC. Conclusion: Our study showed that administration of cyclophosphamide, CMV reactivation, and BK virus positivity were associated with HC. Plasma BK virus PCR titers at days 0, 30, and 60 after transplant were sensitive tools for predicting clinically proven HC.

1 February 2019 in Transfusion Clinique et Biologique
Verified
Journal Article
Closed access
MGM. Gunduz
M. Gunduz
EAE. Atilla
E. Atilla
PAP.A. Atilla
P.A. Atilla
PTP. Topcuoglu
P. Topcuoglu
OIO. Ilhan
O. Ilhan